What this pack is
YAZ is the brand name in this record; drospirenone and ethinyl estradiol is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
YAZGeneric namedrospirenone and ethinyl estradiol
How this medicine works
The current label describes suppression of ovulation as the primary action of combined oral contraceptives, with cervical-mucus and endometrial changes also possibly contributing. Drospirenone also has antimineralocorticoid and antiandrogenic activity. Mechanism explains pharmacology; it does not decide individual suitability, clot risk, testing needs or product choice.
Read source: United States ↗Current regulatory record · reviewed 2026-09-04More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- YAZ
- Generic name
- drospirenone and ethinyl estradiol
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (updated 29 May 2025; SPL v21)
Each blister has 24 light-pink active tablets (drospirenone 3 mg / ethinyl estradiol 0.02 mg per tablet) plus 4 white inert tablets; three blisters per outer pack
- Product code
- NDC 50419-405-03
- Form and route
- YAZ drospirenone/ethinyl estradiol film-coated oral-tablet kit · oral (kit product-identity field)
- Container
- three-blister outer pack
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- drospirenone
- 3 mgfirst ingredient per light-pink active tablet; not to be added to 0.02 mg and not an individual tablet count
- ethinyl estradiol
- 0.02 mgsecond ingredient per light-pink active tablet; the white inert tablets do not contain these two hormones
- Package
- 3 blisters per outer pack
- Labelled appearance
- light-pink active and white inert tablets · round, unscored film-coated tablets · imprint DS on active tablets; DP on inert tablets (each within a regular hexagon)Unscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
YAZ label reading: first separate the two ingredients and active versus inert tablets
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The main reading risk is not one number but the layer it belongs to: two ingredients per active tablet, 24+4 tablets per blister and three blisters per box. The page helps separate those layers but does not generate an individual start, missed-use, make-up, stopping, switching or contraceptive plan.
- Each light-pink active tablet contains drospirenone 3 mg and ethinyl estradiol 0.02 mg; the white tablets are inert. The 3 and 0.02 figures are not added into one comparable strength, and 24, 4, 28 and three blisters are not an individual's tablet count.
- The boxed warning states that women over 35 who smoke should not use YAZ and that smoking increases serious cardiovascular-event risk with combined oral contraceptives. Chest pain, breathing difficulty, one-sided leg swelling or pain, sudden neurologic symptoms or another acute serious concern requires immediate local emergency help, not a web decision.
- Drospirenone has antimineralocorticoid activity. Adrenal, kidney or liver problems, or co-listing potassium, potassium-sparing diuretics, spironolactone, an ACE inhibitor, ARB, aldosterone antagonist, heparin or long-term daily NSAID use requires priority review of potassium and the complete medicine list. The page does not create a stop or separation plan.
- YASMIN, BEYAZ, SAFYRAL, SLYND and other 21+7 or 24+4 products can differ in ingredients, oestrogen, folate, active-tablet count or label. Brand, colour, tablet count or shared drospirenone does not permit self-substitution, assembly or alternation.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-04
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. YAZ drospirenone/ethinyl estradiol public label (updated 29 May 2025; SPL v21) ↗Current regulatory record · reviewed 2026-09-04
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-09-04FDA Drugs@FDA: YAZ NDA 021676 product, RLD/RS and approval history ↗Current regulatory record · reviewed 2026-09-04
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about YAZ (drospirenone and ethinyl estradiol). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
YAZ is the brand in this record and drospirenone and ethinyl estradiol is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. YAZ drospirenone/ethinyl estradiol public label (updated 29 May 2025; SPL v21) ↗Current regulatory record · reviewed 2026-09-04
- FDA Drugs@FDA: YAZ NDA 021676 product, RLD/RS and approval history ↗Current regulatory record · reviewed 2026-09-04
HOW IT WORKS · NOT A TREATMENT PLAN
Mechanism reading: ovulation suppression is primary, not permission to self-select or switch
- ‘Both suppress ovulation’ does not make different combined contraceptives one-for-one substitutes. Hormone identities, per-tablet amounts, active/inert structure, interactions and the target-market label all require separate review.
- Antimineralocorticoid activity explains why potassium and related co-medications need attention, but mechanism cannot calculate individual safety, testing or adjustment of another medicine.
- This page does not extend mechanism into routine whole-genome screening advice. Suitability requires smoking status, age, migraine, clot history, hepatic, renal and adrenal status, the complete medicine list and current label, assessed by the responsible team.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. YAZ drospirenone/ethinyl estradiol public label (updated 29 May 2025; SPL v21) ↗Current regulatory record · reviewed 2026-09-04
- FDA Drugs@FDA: YAZ NDA 021676 product, RLD/RS and approval history ↗Current regulatory record · reviewed 2026-09-04
- FDA: YAZ NDA 021676 original approval letter (16 Mar 2006) ↗Historical public record · reviewed 2026-09-04
SOURCE-TRACEABLE ARCHIVE
YAZdrospirenone and ethinyl estradiol
This page includes an exact current U.S. public-label package panel for YAZ, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA original approval of YAZ NDA 021676
The Drugs@FDA application history lists this date as the ORIG-1 approval. It is a U.S. regulatory-history point, not another market's approval, supply or individual-suitability conclusion.
Primary-source record (open linked document) ↗Current DailyMed SPL v21 updated
The exact NDC, three-blister pack, active/inert tablet distinction, appearance, boxed warning and interaction reading use this public label as the primary source. A label-update date is not channel stock.
Primary-source record (open linked document) ↗
MARKET SCOPE
Market-record boundary
United States
Current product record and public label established under NDA 021676The 3 mg/0.02 mg oral tablet is currently listed by Drugs@FDA as a prescription RLD and RS. This page records the exact public label and pack identity, not real-time supply or purchase eligibility.
Mainland China, EU, Japan and other markets
Current brand, approval, pack and reference status not yet established market by marketNo local product identity, approval, supply, sale eligibility or interchangeability is inferred from the U.S. YAZ name, NDA, RLD/RS status, NDC, 24+4 structure or colours.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
What do 3 mg, 0.02 mg, 24, 4, 28 and 3 each mean?
3 mg and 0.02 mg are the labelled amounts of two different ingredients in each light-pink active tablet. Each blister has 24 active and 4 white inert tablets, 28 total, and the outer pack has three blisters. These numbers are not added and do not by themselves answer how an individual should use the product.
Can the page tell me how many to make up after a missed or wrong-colour tablet?
No. Active versus inert tablet, how many were missed, cycle position, vomiting or diarrhoea and other medicines change which exact-label path applies. Check the patient information for the pack in hand and contact a pharmacist or prescribing team promptly; do not self-make-up from a generic online chart.
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.